Venture Capital Firm Catalio Capital Management Announced today Its $ 400 million fund IV concludes, As reported earlier by Bloomberg. Fund will continue the thesis of the firm of support of healthcare and biotechnology companies.
According to the pitchbook, the firm was established in 2020 and has invested over 100. Catallio’s fund IV, in particular, has already supported 16 companies, including diagnostics company Pinkdx and Drug Discovery Company Superluminal Drugs.
The firm first raised $ 381 million fund III in 2020 and $ 100 million in 2019 in Pitchbook per pitchbook.
Biotech market, in particular, is not immune for the previous year’s enterprise recession, followed by a high interest rate and a cooler IPO market. Last year, the market increased by just $ 12 billion last year, a sharp fall from its peak of $ 152.3 billion in 2023, as Bloomberg reported.
